Coalition for Epidemic Preparedness Innovations & AstraZeneca

Coalition for Epidemic Preparedness Innovations: The Coalition for Epidemic Preparedness Innovations (CEPI) is a key funder, committing approximately $60 million to accelerate the development of Ebola Bundibugyo vaccines, and is crucial in coordinating the global response.

AstraZeneca: AstraZeneca is mentioned in the context of the University of Oxford's vaccine technology, which is similar to their COVID-19 vaccine.

Coalition for Epidemic Preparedness Innovations: Funding vaccine development efforts, including the Oxford and Hilleman candidates. Its investment is critical for accelerating vaccine research.

AstraZeneca: Its COVID-19 vaccine technology is used in the Oxford candidate, but AstraZeneca itself is not directly involved in the Ebola response.

Coalition for Epidemic Preparedness Innovations: The Coalition for Epidemic Preparedness Innovations (CEPI) funds vaccine development and is assessing potential Ebola vaccine candidates, aiming for a rapid response.

AstraZeneca: AstraZeneca was involved in the development of the COVID-19 vaccine platform that is now being considered for a Bundibugyo ebolavirus vaccine, showcasing its role in vaccine innovation.